Chemed (CHE) EBITDA (2009 - 2026)

Chemed (CHE) has reported EBITDA for 18 consecutive years, with $98.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA fell 8.62% year-over-year to $98.9 million; the TTM figure through Mar 2026 stood at $383.5 million (down 13.23% YoY), while the FY2025 annual figure was $392.8 million, down 6.33% from the prior year.
• EBITDA came in at $98.9 million for Q1 2026 at Chemed, down from $114.4 million in the prior quarter.
• The five-year high for EBITDA was $127.1 million in Q4 2024, with the low at -$180.8 million in Q4 2022.
• Average EBITDA over 5 years is $83.6 million, with a median of $99.7 million recorded in 2023.
• The largest YoY upside for EBITDA was 168.8% in 2023 against a maximum downside of 21.51% in 2023.
• Year by year, EBITDA stood at -$180.8 million in 2022, then jumped by 168.8% to $124.4 million in 2023, then gained by 2.19% to $127.1 million in 2024, then slipped by 10.01% to $114.4 million in 2025, then dropped by 13.58% to $98.9 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $98.9 million, $114.4 million, and $88.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.